Abstract: SA-PO680
Stone Frequency Determines Health-Related Quality of Life (HRQoL) in Cystine Stone Formers (CSF)
Session Information
- Bone and Mineral Metabolism: Clinical - II
October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Bone and Mineral Metabolism
- 402 Bone and Mineral Metabolism: Clinical
Authors
- Modersitzki, Frank, New York University School of Medicine, New York, New York, United States
- Goldfarb, David S., New York University School of Medicine, New York, New York, United States
Group or Team Name
- Rare Kidney Stone Consortium
Background
CSF have lower HRQoL compared to US Standard Population. We have shown previously that HRQoL results need to be controlled for the last stone event and comorbidities. We now show the first longitudinal HRQoL domain profiles for baseline and two yearly follow-ups.
Methods
CSF were enrolled from the RKSC registry. HRQoL was measured with the generic non-disease specific SF-36v2. Results were calculated as norm-based scores (NBS) based on US Standard Population (Domain score mean = 50). We selected 3 stone frequency groups (SFG): low (stone-free during observation period), medium (minimum of one stone event between 31 - 365 days) and high (stone event always present within 30 days of the survey), and compared the groups' HRQoL at baseline and second follow-up.
Results
We scored 386 surveys. 78 participants (32 males and 46 females) were compared at baseline and 2 follow-up assessments. Mean age was 45 years (male 44/ female 46). Repeated measure ANOVA showed no difference within each SFG over time (Fig 1). However, domain scores were significantly different between SFG's (p<0.05) at each time point, with low>medium>high stone frequency. Whether surgical intervention was required, and type, were not predictors of HRQoL outcomes. Better HRQoL tracked with lower cystine excretion per liter on 24h urine collections; lower cystine capacity and higher citrate doses were underpowered (NS).
Conclusion
CSF with high stone event rates experience worse HRQoL over time, while CSF with no stone events achieved better HRQoL than US standard. Clinnical data suggest that the high SFG is undertreated.
Clinical Data
| Stone Frequency Group | Cystine/liter* | Citrate use (mg/d) | Cystine Capacity |
| High | 463 (370), 11 | 51 (40), 10 | -110 (215), 8 |
| Medium | 270 (124), 21 | 68 (27), 13 | 4 (130), 16 |
| Low | 231 (100), 15 | 69 (31), 11 | 26 (96), 10 |
mean (SD), n; *p=0.015
Funding
- NIDDK Support